Literature DB >> 2049234

Lack of effect of oral contraceptive use on the pharmacokinetics of quinine.

S Wanwimolruk1, S Kaewvichit, O Tanthayaphinant, C Suwannarach, A Oranratnachai.   

Abstract

The pharmacokinetics of quinine after a single 600 mg oral dose of quinine sulphate were studied in seven female subjects who used oral contraceptives and in seven age-matched female controls who did not. There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h). The mean elimination half-life of quinine in the oral contraceptives user group (12.5 +/- 1.9 h) was similar (P greater than 0.05) to that in the control group (11.8 +/- 2.7 h). The oral clearance of quinine in the oral contraceptive user group was 0.133 +/- 0.055 l h-1 kg-1 (range 0.073-0.233) and was not significantly different (P greater than 0.05) from that observed in the control group (0.125 +/- 0.025 l h-1 kg-1, range 0.075-0.148).

Entities:  

Keywords:  Asia; Contraception; Contraceptive Methods--pharmacodynamics; Control Groups; Developing Countries; Drug Interactions; Drugs--analysis; Drugs--side effects; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Oral Contraceptives--pharmacodynamics; Research Methodology; Southeastern Asia; Thailand; Treatment

Mesh:

Substances:

Year:  1991        PMID: 2049234      PMCID: PMC1368387          DOI: 10.1111/j.1365-2125.1991.tb05509.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.

Authors:  J Karbwang; S Looareesuwan; D J Back; S Migasana; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

2.  Alterations in prednisolone disposition as a result of oral contraceptive use and dose.

Authors:  P J Meffin; L M Wing; B C Sallustio; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

3.  Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis.

Authors:  S Wanwimolruk; D J Birkett; P M Brooks
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

5.  High-performance liquid chromatographic separation and isolation of quinidine and quinine metabolites in rat urine.

Authors:  S E Barrow; A A Taylor; E C Horning; M G Horning
Journal:  J Chromatogr       Date:  1980-02-08

6.  Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.

Authors:  G P Stoehr; P D Kroboth; R P Juhl; D B Wender; J P Phillips; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

7.  Oxidation of quinidine by human liver cytochrome P-450.

Authors:  F P Guengerich; D Müller-Enoch; I A Blair
Journal:  Mol Pharmacol       Date:  1986-09       Impact factor: 4.436

8.  Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids.

Authors:  D M Chambers; G C Jefferson; M Chambers; N B Loudon
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

9.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Authors:  F P Guengerich; M V Martin; P H Beaune; P Kremers; T Wolff; D J Waxman
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

10.  Quinine disposition kinetics.

Authors:  N J White; P Chanthavanich; S Krishna; C Bunch; K Silamut
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

  10 in total
  9 in total

1.  Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.

Authors:  Shanna Babalonis; Aidan J Hampson; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  J Clin Pharmacol       Date:  2015-07-29       Impact factor: 3.126

2.  The reproducibility of quinine bioavailability.

Authors:  G Paintaud; G Alván; O Ericsson
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

3.  Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Authors:  K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

Review 4.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

5.  Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.

Authors:  Daniel W Bougie; Peter R Wilker; Richard H Aster
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Chalcroft
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

7.  Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.

Authors:  S Wanwimolruk; W Kang; P F Coville; S Viriyayudhakorn; S Thitiarchakul
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

8.  The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers.

Authors:  U K Walle; T C Fagan; M J Topmiller; E C Conradi; T Walle
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

9.  Cigarette smoking enhances the elimination of quinine.

Authors:  S Wanwimolruk; S M Wong; P F Coville; S Viriyayudhakorn; S Thitiarchakul
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.